Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 313

1.

The Miami Monkey: A Sunny Alternative to the Berlin Patient.

Liberatore RA, Ho DD.

Immunity. 2019 Mar 19;50(3):537-539. doi: 10.1016/j.immuni.2019.02.010.

PMID:
30893580
2.

Engineering multi-specific antibodies against HIV-1.

Padte NN, Yu J, Huang Y, Ho DD.

Retrovirology. 2018 Aug 29;15(1):60. doi: 10.1186/s12977-018-0439-9. Review.

3.

Fusion Energy Output Greater than the Kinetic Energy of an Imploding Shell at the National Ignition Facility.

Le Pape S, Berzak Hopkins LF, Divol L, Pak A, Dewald EL, Bhandarkar S, Bennedetti LR, Bunn T, Biener J, Crippen J, Casey D, Edgell D, Fittinghoff DN, Gatu-Johnson M, Goyon C, Haan S, Hatarik R, Havre M, Ho DD, Izumi N, Jaquez J, Khan SF, Kyrala GA, Ma T, Mackinnon AJ, MacPhee AG, MacGowan BJ, Meezan NB, Milovich J, Millot M, Michel P, Nagel SR, Nikroo A, Patel P, Ralph J, Ross JS, Rice NG, Strozzi D, Stadermann M, Volegov P, Yeamans C, Weber C, Wild C, Callahan D, Hurricane OA.

Phys Rev Lett. 2018 Jun 15;120(24):245003. doi: 10.1103/PhysRevLett.120.245003.

PMID:
29956968
4.

Potential of conventional & bispecific broadly neutralizing antibodies for prevention of HIV-1 subtype A, C & D infections.

Wagh K, Seaman MS, Zingg M, Fitzsimons T, Barouch DH, Burton DR, Connors M, Ho DD, Mascola JR, Nussenzweig MC, Ravetch J, Gautam R, Martin MA, Montefiori DC, Korber B.

PLoS Pathog. 2018 Mar 5;14(3):e1006860. doi: 10.1371/journal.ppat.1006860. eCollection 2018 Mar.

5.

In Vivo Production of Monoclonal Antibodies by Gene Transfer via Electroporation Protects against Lethal Influenza and Ebola Infections.

Andrews CD, Luo Y, Sun M, Yu J, Goff AJ, Glass PJ, Padte NN, Huang Y, Ho DD.

Mol Ther Methods Clin Dev. 2017 Sep 20;7:74-82. doi: 10.1016/j.omtm.2017.09.003. eCollection 2017 Dec 15.

6.

DNA Vaccination by Electroporation Amplifies Broadly Cross-Restricted Public TCR Clonotypes Shared with HIV Controllers.

Mukhopadhyay M, Galperin M, Patgaonkar M, Vasan S, Ho DD, Nouël A, Claireaux M, Benati D, Lambotte O, Huang Y, Chakrabarti LA.

J Immunol. 2017 Nov 15;199(10):3437-3452. doi: 10.4049/jimmunol.1700953. Epub 2017 Oct 9.

7.

Cabotegravir long acting injection protects macaques against intravenous challenge with SIVmac251.

Andrews CD, Bernard LS, Poon AY, Mohri H, Gettie N, Spreen WR, Gettie A, Russell-Lodrigue K, Blanchard J, Hong Z, Ho DD, Markowitz M.

AIDS. 2017 Feb 20;31(4):461-467. doi: 10.1097/QAD.0000000000001343.

8.

Distinct HIV-1 Neutralization Potency Profiles of Ibalizumab-Based Bispecific Antibodies.

Song R, Pace C, Seaman MS, Fang Q, Sun M, Andrews CD, Wu A, Padte NN, Ho DD.

J Acquir Immune Defic Syndr. 2016 Dec 1;73(4):365-373.

9.

Engineered Bispecific Antibodies with Exquisite HIV-1-Neutralizing Activity.

Huang Y, Yu J, Lanzi A, Yao X, Andrews CD, Tsai L, Gajjar MR, Sun M, Seaman MS, Padte NN, Ho DD.

Cell. 2016 Jun 16;165(7):1621-1631. doi: 10.1016/j.cell.2016.05.024.

10.

Optimization of the Solubility of HIV-1-Neutralizing Antibody 10E8 through Somatic Variation and Structure-Based Design.

Kwon YD, Georgiev IS, Ofek G, Zhang B, Asokan M, Bailer RT, Bao A, Caruso W, Chen X, Choe M, Druz A, Ko SY, Louder MK, McKee K, O'Dell S, Pegu A, Rudicell RS, Shi W, Wang K, Yang Y, Alger M, Bender MF, Carlton K, Cooper JW, Blinn J, Eudailey J, Lloyd K, Parks R, Alam SM, Haynes BF, Padte NN, Yu J, Ho DD, Huang J, Connors M, Schwartz RM, Mascola JR, Kwong PD.

J Virol. 2016 Jun 10;90(13):5899-5914. doi: 10.1128/JVI.03246-15. Print 2016 Jul 1.

11.

Immunogenicity and protective efficacy of recombinant Clostridium difficile flagellar protein FliC.

Ghose C, Eugenis I, Sun X, Edwards AN, McBride SM, Pride DT, Kelly CP, Ho DD.

Emerg Microbes Infect. 2016 Feb 3;5:e8. doi: 10.1038/emi.2016.8.

12.

TDA Strategic Plan 2020: Helping All TDA Member Dentists Succeed.

Ho DD.

Tex Dent J. 2015 Oct;132(10):850-3. No abstract available.

PMID:
26710595
13.

Immunogenicity and protective efficacy of Clostridium difficile spore proteins.

Ghose C, Eugenis I, Edwards AN, Sun X, McBride SM, Ho DD.

Anaerobe. 2016 Feb;37:85-95. doi: 10.1016/j.anaerobe.2015.12.001. Epub 2015 Dec 11.

14.

V1/V2 Neutralizing Epitope is Conserved in Divergent Non-M Groups of HIV-1.

Morgand M, Bouvin-Pley M, Plantier JC, Moreau A, Alessandri E, Simon F, Pace CS, Pancera M, Ho DD, Poignard P, Bjorkman PJ, Mouquet H, Nussenzweig MC, Kwong PD, Baty D, Chames P, Braibant M, Barin F.

J Acquir Immune Defic Syndr. 2016 Mar 1;71(3):237-45. doi: 10.1097/QAI.0000000000000854.

15.

Colocalization of a CD1d-Binding Glycolipid with a Radiation-Attenuated Sporozoite Vaccine in Lymph Node-Resident Dendritic Cells for a Robust Adjuvant Effect.

Li X, Kawamura A, Andrews CD, Miller JL, Wu D, Tsao T, Zhang M, Oren D, Padte NN, Porcelli SA, Wong CH, Kappe SH, Ho DD, Tsuji M.

J Immunol. 2015 Sep 15;195(6):2710-21. doi: 10.4049/jimmunol.1403017. Epub 2015 Aug 7.

16.

First high-convergence cryogenic implosion in a near-vacuum hohlraum.

Berzak Hopkins LF, Meezan NB, Le Pape S, Divol L, Mackinnon AJ, Ho DD, Hohenberger M, Jones OS, Kyrala G, Milovich JL, Pak A, Ralph JE, Ross JS, Benedetti LR, Biener J, Bionta R, Bond E, Bradley D, Caggiano J, Callahan D, Cerjan C, Church J, Clark D, Döppner T, Dylla-Spears R, Eckart M, Edgell D, Field J, Fittinghoff DN, Gatu Johnson M, Grim G, Guler N, Haan S, Hamza A, Hartouni EP, Hatarik R, Herrmann HW, Hinkel D, Hoover D, Huang H, Izumi N, Khan S, Kozioziemski B, Kroll J, Ma T, MacPhee A, McNaney J, Merrill F, Moody J, Nikroo A, Patel P, Robey HF, Rygg JR, Sater J, Sayre D, Schneider M, Sepke S, Stadermann M, Stoeffl W, Thomas C, Town RP, Volegov PL, Wild C, Wilde C, Woerner E, Yeamans C, Yoxall B, Kilkenny J, Landen OL, Hsing W, Edwards MJ.

Phys Rev Lett. 2015 May 1;114(17):175001. Epub 2015 Apr 29.

PMID:
25978240
17.

Neutralization properties of simian immunodeficiency viruses infecting chimpanzees and gorillas.

Barbian HJ, Decker JM, Bibollet-Ruche F, Galimidi RP, West AP Jr, Learn GH, Parrish NF, Iyer SS, Li Y, Pace CS, Song R, Huang Y, Denny TN, Mouquet H, Martin L, Acharya P, Zhang B, Kwong PD, Mascola JR, Verrips CT, Strokappe NM, Rutten L, McCoy LE, Weiss RA, Brown CS, Jackson R, Silvestri G, Connors M, Burton DR, Shaw GM, Nussenzweig MC, Bjorkman PJ, Ho DD, Farzan M, Hahn BH.

MBio. 2015 Apr 21;6(2). pii: e00296-15. doi: 10.1128/mBio.00296-15.

18.

A long-acting integrase inhibitor protects female macaques from repeated high-dose intravaginal SHIV challenge.

Andrews CD, Yueh YL, Spreen WR, St Bernard L, Boente-Carrera M, Rodriguez K, Gettie A, Russell-Lodrigue K, Blanchard J, Ford S, Mohri H, Cheng-Mayer C, Hong Z, Ho DD, Markowitz M.

Sci Transl Med. 2015 Jan 14;7(270):270ra4. doi: 10.1126/scitranslmed.3010298.

19.

Improving Mycobacterium bovis bacillus Calmette-Guèrin as a vaccine delivery vector for viral antigens by incorporation of glycolipid activators of NKT cells.

Venkataswamy MM, Ng TW, Kharkwal SS, Carreño LJ, Johnson AJ, Kunnath-Velayudhan S, Liu Z, Bittman R, Jervis PJ, Cox LR, Besra GS, Wen X, Yuan W, Tsuji M, Li X, Ho DD, Chan J, Lee S, Frothingham R, Haynes BF, Panas MW, Gillard GO, Sixsmith JD, Korioth-Schmitz B, Schmitz JE, Larsen MH, Jacobs WR Jr, Porcelli SA.

PLoS One. 2014 Sep 25;9(9):e108383. doi: 10.1371/journal.pone.0108383. eCollection 2014.

20.

Rational design and characterization of the novel, broad and potent bispecific HIV-1 neutralizing antibody iMabm36.

Sun M, Pace CS, Yao X, Yu F, Padte NN, Huang Y, Seaman MS, Li Q, Ho DD.

J Acquir Immune Defic Syndr. 2014 Aug 15;66(5):473-83. doi: 10.1097/QAI.0000000000000218.

21.

Long-acting integrase inhibitor protects macaques from intrarectal simian/human immunodeficiency virus.

Andrews CD, Spreen WR, Mohri H, Moss L, Ford S, Gettie A, Russell-Lodrigue K, Bohm RP, Cheng-Mayer C, Hong Z, Markowitz M, Ho DD.

Science. 2014 Mar 7;343(6175):1151-4. doi: 10.1126/science.1248707. Epub 2014 Mar 4.

22.

A replicating modified vaccinia tiantan strain expressing an avian-derived influenza H5N1 hemagglutinin induce broadly neutralizing antibodies and cross-clade protective immunity in mice.

Xiao H, Liu L, Zhu Q, Tan Z, Yu W, Tang X, Zhan D, Du Y, Wang H, Liu D, Li Z, Yuen KY, Ho DD, Gao GF, Chen Z.

PLoS One. 2013 Dec 17;8(12):e83274. doi: 10.1371/journal.pone.0083274. eCollection 2013. Erratum in: PLoS One. 2014;9(12):e115925.

23.

A glycolipid adjuvant, 7DW8-5, enhances CD8+ T cell responses induced by an adenovirus-vectored malaria vaccine in non-human primates.

Padte NN, Boente-Carrera M, Andrews CD, McManus J, Grasperge BF, Gettie A, Coelho-dos-Reis JG, Li X, Wu D, Bruder JT, Sedegah M, Patterson N, Richie TL, Wong CH, Ho DD, Vasan S, Tsuji M.

PLoS One. 2013 Oct 25;8(10):e78407. doi: 10.1371/journal.pone.0078407. eCollection 2013.

24.

Strategic addition of an N-linked glycan to a monoclonal antibody improves its HIV-1-neutralizing activity.

Song R, Oren DA, Franco D, Seaman MS, Ho DD.

Nat Biotechnol. 2013 Nov;31(11):1047-52. doi: 10.1038/nbt.2677. Epub 2013 Oct 6.

25.

Bispecific antibodies directed to CD4 domain 2 and HIV envelope exhibit exceptional breadth and picomolar potency against HIV-1.

Pace CS, Song R, Ochsenbauer C, Andrews CD, Franco D, Yu J, Oren DA, Seaman MS, Ho DD.

Proc Natl Acad Sci U S A. 2013 Aug 13;110(33):13540-5. doi: 10.1073/pnas.1304985110. Epub 2013 Jul 22.

27.

The incidence of primary antibiotic resistance of Helicobacter pylori in Vietnam.

Binh TT, Shiota S, Nguyen LT, Ho DD, Hoang HH, Ta L, Trinh DT, Fujioka T, Yamaoka Y.

J Clin Gastroenterol. 2013 Mar;47(3):233-8. doi: 10.1097/MCG.0b013e3182676e2b.

28.

Anti-CD4 monoclonal antibody ibalizumab exhibits breadth and potency against HIV-1, with natural resistance mediated by the loss of a V5 glycan in envelope.

Pace CS, Fordyce MW, Franco D, Kao CY, Seaman MS, Ho DD.

J Acquir Immune Defic Syndr. 2013 Jan 1;62(1):1-9. doi: 10.1097/QAI.0b013e3182732746.

PMID:
23023102
29.

HIV-1 and influenza antigens synthetically linked to IgG2a Fc elicit superior humoral responses compared to unmodified antigens in mice.

Zaharatos GJ, Yu J, Pace C, Song Y, Vasan S, Ho DD, Huang Y.

Vaccine. 2011 Dec 9;30(1):42-50. doi: 10.1016/j.vaccine.2011.10.056. Epub 2011 Nov 4.

PMID:
22064264
30.

Sequence and structural convergence of broad and potent HIV antibodies that mimic CD4 binding.

Scheid JF, Mouquet H, Ueberheide B, Diskin R, Klein F, Oliveira TY, Pietzsch J, Fenyo D, Abadir A, Velinzon K, Hurley A, Myung S, Boulad F, Poignard P, Burton DR, Pereyra F, Ho DD, Walker BD, Seaman MS, Bjorkman PJ, Chait BT, Nussenzweig MC.

Science. 2011 Sep 16;333(6049):1633-7. doi: 10.1126/science.1207227. Epub 2011 Jul 14.

31.

In vivo electroporation enhances the immunogenicity of an HIV-1 DNA vaccine candidate in healthy volunteers.

Vasan S, Hurley A, Schlesinger SJ, Hannaman D, Gardiner DF, Dugin DP, Boente-Carrera M, Vittorino R, Caskey M, Andersen J, Huang Y, Cox JH, Tarragona-Fiol T, Gill DK, Cheeseman H, Clark L, Dally L, Smith C, Schmidt C, Park HH, Kopycinski JT, Gilmour J, Fast P, Bernard R, Ho DD.

PLoS One. 2011;6(5):e19252. doi: 10.1371/journal.pone.0019252. Epub 2011 May 16.

32.

Broadly neutralizing DNA vaccine with specific mutation alters the antigenicity and sugar-binding activities of influenza hemagglutinin.

Chen MW, Liao HY, Huang Y, Jan JT, Huang CC, Ren CT, Wu CY, Cheng TJ, Ho DD, Wong CH.

Proc Natl Acad Sci U S A. 2011 Mar 1;108(9):3510-5. doi: 10.1073/pnas.1019744108. Epub 2011 Feb 14.

33.

CD40L-containing virus-like particle as a candidate HIV-1 vaccine targeting dendritic cells.

Franco D, Liu W, Gardiner DF, Hahn BH, Ho DD.

J Acquir Immune Defic Syndr. 2011 Apr 15;56(5):393-400. doi: 10.1097/QAI.0b013e31820b844e.

PMID:
21239998
34.

Identification of the DC-SIGN-interactive domains on the envelope glycoprotein of HIV-1 CRF07_BC.

Liao CF, Wang SF, Lin YT, Ho DD, Chen YM.

AIDS Res Hum Retroviruses. 2011 Aug;27(8):831-9. doi: 10.1089/AID.2010.0215. Epub 2011 Jan 17.

PMID:
21142800
35.

Crystal structure of HIV-1 primary receptor CD4 in complex with a potent antiviral antibody.

Freeman MM, Seaman MS, Rits-Volloch S, Hong X, Kao CY, Ho DD, Chen B.

Structure. 2010 Dec 8;18(12):1632-41. doi: 10.1016/j.str.2010.09.017.

36.

Helicobacter pylori infection and gastroduodenal diseases in Vietnam: a cross-sectional, hospital-based study.

Nguyen TL, Uchida T, Tsukamoto Y, Trinh DT, Ta L, Mai BH, Le SH, Thai KD, Ho DD, Hoang HH, Matsuhisa T, Okimoto T, Kodama M, Murakami K, Fujioka T, Yamaoka Y, Moriyama M.

BMC Gastroenterol. 2010 Sep 30;10:114. doi: 10.1186/1471-230X-10-114.

37.

Polyreactivity increases the apparent affinity of anti-HIV antibodies by heteroligation.

Mouquet H, Scheid JF, Zoller MJ, Krogsgaard M, Ott RG, Shukair S, Artyomov MN, Pietzsch J, Connors M, Pereyra F, Walker BD, Ho DD, Wilson PC, Seaman MS, Eisen HN, Chakraborty AK, Hope TJ, Ravetch JV, Wardemann H, Nussenzweig MC.

Nature. 2010 Sep 30;467(7315):591-5. doi: 10.1038/nature09385.

38.

Design of a potent CD1d-binding NKT cell ligand as a vaccine adjuvant.

Li X, Fujio M, Imamura M, Wu D, Vasan S, Wong CH, Ho DD, Tsuji M.

Proc Natl Acad Sci U S A. 2010 Jul 20;107(29):13010-5. doi: 10.1073/pnas.1006662107. Epub 2010 Jul 2.

39.

Evaluation of yellow fever virus 17D strain as a new vector for HIV-1 vaccine development.

Franco D, Li W, Qing F, Stoyanov CT, Moran T, Rice CM, Ho DD.

Vaccine. 2010 Aug 9;28(35):5676-85. doi: 10.1016/j.vaccine.2010.06.052. Epub 2010 Jun 29.

PMID:
20600494
40.

Epitope mapping of ibalizumab, a humanized anti-CD4 monoclonal antibody with anti-HIV-1 activity in infected patients.

Song R, Franco D, Kao CY, Yu F, Huang Y, Ho DD.

J Virol. 2010 Jul;84(14):6935-42. doi: 10.1128/JVI.00453-10. Epub 2010 May 12.

41.

Prevention of mother-to-child transmission of HIV-1 using highly active antiretroviral therapy in rural Yunnan, China.

Zhou Z, Meyers K, Li X, Chen Q, Qian H, Lao Y, Geng E, Fan Y, Yang S, Chiu M, Ho DD.

J Acquir Immune Defic Syndr. 2010 Feb;53 Suppl 1:S15-22. doi: 10.1097/QAI.0b013e3181c7d47b.

PMID:
20104104
42.

Phase 1 safety and immunogenicity evaluation of ADMVA, a multigenic, modified vaccinia Ankara-HIV-1 B'/C candidate vaccine.

Vasan S, Schlesinger SJ, Chen Z, Hurley A, Lombardo A, Than S, Adesanya P, Bunce C, Boaz M, Boyle R, Sayeed E, Clark L, Dugin D, Boente-Carrera M, Schmidt C, Fang Q, LeiBa, Huang Y, Zaharatos GJ, Gardiner DF, Caskey M, Seamons L, Ho M, Dally L, Smith C, Cox J, Gill D, Gilmour J, Keefer MC, Fast P, Ho DD.

PLoS One. 2010 Jan 25;5(1):e8816. doi: 10.1371/journal.pone.0008816.

43.

Phase 1 safety and immunogenicity evaluation of ADVAX, a multigenic, DNA-based clade C/B' HIV-1 candidate vaccine.

Vasan S, Schlesinger SJ, Huang Y, Hurley A, Lombardo A, Chen Z, Than S, Adesanya P, Bunce C, Boaz M, Boyle R, Sayeed E, Clark L, Dugin D, Schmidt C, Song Y, Seamons L, Dally L, Ho M, Smith C, Markowitz M, Cox J, Gill DK, Gilmour J, Keefer MC, Fast P, Ho DD.

PLoS One. 2010 Jan 25;5(1):e8617. doi: 10.1371/journal.pone.0008617.

44.

A case series of 104 women infected with HIV-1 via blood transfusion postnatally: high rate of HIV-1 transmission to infants through breast-feeding.

Liang K, Gui X, Zhang YZ, Zhuang K, Meyers K, Ho DD.

J Infect Dis. 2009 Sep 1;200(5):682-6. doi: 10.1086/605123.

PMID:
19627245
45.

A DNA vaccine targeting the receptor-binding domain of Clostridium difficile toxin A.

Gardiner DF, Rosenberg T, Zaharatos J, Franco D, Ho DD.

Vaccine. 2009 Jun 2;27(27):3598-604. doi: 10.1016/j.vaccine.2009.03.058. Epub 2009 Apr 9.

46.

The changing face of HIV in China.

Lu L, Jia M, Ma Y, Yang L, Chen Z, Ho DD, Jiang Y, Zhang L.

Nature. 2008 Oct 2;455(7213):609-11. doi: 10.1038/455609a.

PMID:
18833270
47.

A recoding method to improve the humoral immune response to an HIV DNA vaccine.

Huang Y, Krasnitz M, Rabadan R, Witten DM, Song Y, Levine AJ, Ho DD, Robins H.

PLoS One. 2008 Sep 15;3(9):e3214. doi: 10.1371/journal.pone.0003214.

48.

A consensus-hemagglutinin-based DNA vaccine that protects mice against divergent H5N1 influenza viruses.

Chen MW, Cheng TJ, Huang Y, Jan JT, Ma SH, Yu AL, Wong CH, Ho DD.

Proc Natl Acad Sci U S A. 2008 Sep 9;105(36):13538-43. doi: 10.1073/pnas.0806901105. Epub 2008 Sep 2.

49.

HIV-1 at 25.

Ho DD, Bieniasz PD.

Cell. 2008 May 16;133(4):561-5. doi: 10.1016/j.cell.2008.05.003.

50.

Isolation and quantitation of HIV in peripheral blood.

Koup RA, Ho DD, Poli G, Fauci AS.

Curr Protoc Immunol. 2001 May;Chapter 12:Unit 12.2. doi: 10.1002/0471142735.im1202s05.

PMID:
18432710

Supplemental Content

Support Center